1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PharmaEngine, Inc.

PharmaEngine, Inc.

TTPEX:4162
56.20
TWD
0.00
(0.00%)
3.74EPS
16.28P/E
8.76BMarket Cap
Nov 11Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.28
1.58
3.46
7.75
5.8
1.99
2.16
7.25
4.53
4.56
5.35
17.57
6.34
7.13
Basic EPS, GAAP
-0.87
0.85
2.69
4.71
2.63
0.88
0.29
4.15
2.95
2.22
1.91
12.19
2.7
3.75
Free Cash Flow per Basic Share
-0.35
0.9
2.98
5.93
-2.31
5.06
0.11
0.44
6.43
1.38
1.79
3.17
12.02
3.76
Dividend per Share
- -
- -
0.7
0.69
1.67
2
1
0.5
2.52
2.7
2
1.5
6
- -
Book Value per Share
18.81
19.96
21.63
25.97
26.58
25.19
24.08
27.55
27.43
26.95
26.89
37.58
34.28
34.17
Tangible Book Value per Share
18.81
19.96
21.63
25.96
26.58
25.18
24.07
27.54
27.42
26.93
26.87
37.57
34.28
34.17
Basic Weighted Avg Shares
135
145
147
147
147
147
146
146
145
144
144
144
144
144
Sales/Revenue/Turnover
37
229
507
1,135
854
293
314
1,056
655
654
768
2,523
911
1,025
Operating Margin (%)
-372.95
30.81
64.53
71.21
71.8
14.46
10.38
76.68
55.35
43.21
36.11
81.37
46.68
47.32
Depreciation Expense
- -
- -
2
3
3
3
7
13
10
9
9
9
10
11
Net Income, GAAP
-118
124
394
690
387
129
43
604
426
319
275
1,751
388
539
Effective Tax Rate (%)
- -
0.59
3.19
17.7
22.12
21.01
14.33
19.69
21.89
18.77
18.74
19.05
23.89
16.66
Profit Margin (%)
-315.1
53.97
77.68
60.77
45.34
44.09
13.55
57.22
65.06
48.72
35.78
69.39
42.53
52.56
Working Capital
2,693
2,897
3,097
3,786
3,871
3,667
3,440
3,985
3,921
3,847
3,839
5,384
4,898
4,887
LT Debt
- -
- -
- -
- -
- -
- -
22
11
- -
15
7
- -
33
29
Total Equity
2,718
2,927
3,159
3,799
3,911
3,694
3,483
4,011
3,939
3,872
3,863
5,400
4,926
4,910
Return on Invested Capital (%)
- -
2.48
10.36
18.83
12.07
0.87
0.77
17.15
7.06
5.85
5.8
34.58
6.03
8.34
Return on Capital (%)
- -
4.38
12.94
19.81
10.04
3.4
1.18
16.02
10.68
8.13
7.07
37.72
7.47
11.22
Return on Common Equity (%)
-5.41
4.38
12.95
19.82
10.04
3.4
1.19
16.13
10.72
8.16
7.1
37.81
7.51
11.26

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
9
9
9
LT Borrowings
- -
- -
- -
LT Finance Leases
33
31
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
144
144
144
Market Capitalization
10,115
8,261
8,764

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,085
5,219
5,366
Cash, Cash Equivalents & STI
4,717
4,975
5,072
Accounts Receivable, Net
84
61
77
Inventories
40
24
38
Total Current Liabilities
187
179
479
Payables & Accruals
- -
- -
- -
ST Debt
9
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.44%
5.45%
-8.78%
Free Cash Flow
150.36%
331.22%
279.2%
Net Income, GAAP
160.88%
78.24%
-77.86%
Sales/Revenue/Turnover
42.07%
28.81%
-63.88%
Total Cash Common Dividend
71.6%
131.09%
300.07%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
164
262
218
1,879
2,523
2025
187
197
242
285
911
2026
240
258
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.57
1.11
0.64
9.87
12.19
2025
0.71
0.12
0.95
0.91
2.7
2026
0.96
0.93
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.5
2025
- -
- -
- -
- -
6
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hong Ren Wang
Full Time Employees
45
Sector
Health technology
Industry
Pharmaceuticals: major
Address
10 Minsheng East Road Taipei TP Taiwan 104
IPO Date
Sep 1, 2011
Website
pharmaengine.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PharmaEngine, Inc. (4162.TWO) is a Taiwan-based biopharmaceutical company that develops and commercializes oncology therapies using a virtual pharmaceutical company business model. Founded in 2002 and headquartered at 11F, No. 10, Section 3, Minsheng East Road, Taipei, Taiwan, the company focuses on precision oncology, particularly DNA damage response pathways, and operates primarily in Taiwan while marketing products globally through partnerships in the U.S., Europe, and Asia. Its core products include ONIVYDE, a nanoliposomal irinotecan formulation approved for metastatic pancreatic adenocarcinoma in combination with fluorouracil and leucovorin, and previously LIPORAXEL; the research and development pipeline features PEP07, an oral CHK1 inhibitor in Phase 1 trials for hematological tumors, mantle cell lymphoma, and solid tumors, and PEP08 (PE-0260), a PRMT5 inhibitor with TFDA approval for Phase 1 trials in solid tumors, first patient dosed, and HREC/TGA acknowledgment in Australia. Recent developments encompass ONIVYDE's inclusion in Taiwan's National Health Insurance for first-line metastatic pancreatic adenocarcinoma treatment with oxaliplatin, fluorouracil, and leucovorin; U.S. FDA, TFDA, and EMA approvals for its first-line regimen; a US$50 million milestone payment received in February 2025 from 2024 sales in Europe and Asia; an exclusive distribution agreement with Haihe Biopharma for LIPORAXEL in November 2024; first patient dosing in PEP07's Phase 1 trial in April 2024; presentations at AACR 2025; and recognition as a 2025 Taiwan Best-in-Class Company by the Taiwan Institute of Directors, topping profit champions and ranking second in growth.